FDA Approves Vepdegestrant for Advanced ESR1-Mutated Breast Cancer

Key Facts

• FDA Approval Date: May 1, 2026
• Drug Name: Vepdegestrant (Brand: Veppanu)
• Indication: Adults with advanced or metastatic ER-positive, HER2-negative, ESR1-mutated breast cancer
• Developers: Arvinas Operations, Inc. and Pfizer Inc.
• Drug Class: Proteolysis Targeting Chimera (PROTAC); first FDA-approved drug of this class
• Administration: Oral therapy, 200 mg once daily with food until disease progression or unacceptable toxicity
• Companion Diagnostic: Guardant360 CDx approved simultaneously to detect ESR1 mutations
• Clinical Trial: Phase 3 VERITAC-2 (NCT05654623); in ESR1-mutated patients, median progression-free survival of 5.0 months with vepdegestrant versus 2.1 months with fulvestrant; objective response rate 19% vs 4%
• Warnings and Precautions: QTc interval prolongation, embryo-fetal toxicity
• Regulatory Process: FDA approval granted one month ahead of goal date using Assessment Aid review process

Background & Context

Breast cancer expressing estrogen receptor (ER) but lacking human epidermal growth factor receptor 2 (HER2) frequently undergoes treatment using endocrine therapies. However, resistance often develops due to mutations in the ESR1 gene. Vepdegestrant introduces a novel therapeutic mechanism by functioning as a PROTAC, which induces selective degradation of disease-driving proteins rather than merely inhibiting them. This oral therapy is designed for patients with ESR1-mutated disease whose cancer progressed despite prior endocrine therapy. The approval is significant because it enables personalized medicine via a companion diagnostic test (Guardant360 CDx) to identify suitable patients through ESR1 mutation detection.

Why This Matters for Exams

This milestone represents the FDA's first approval of a PROTAC drug, marking advancement in targeted protein degradation therapies. Understanding vepdegestrant's clinical indication, unique mechanism, companion diagnostic approach, clinical trial outcomes, and regulatory pathway is relevant for competitive examinations covering pharmacology, oncology therapeutics, biotechnology innovations, and regulatory affairs. Details such as the drug's developers (Arvinas and Pfizer) and safety warnings have direct importance in medical, pharmacy, and life sciences curricula.

Points to Remember

• Vepdegestrant is the first FDA-approved Proteolysis Targeting Chimera (PROTAC) drug as of May 1, 2026.
• Approved for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
• Delivered orally at 200 mg once daily with food until disease progression or unacceptable toxicity.
• Companion diagnostic Guardant360 CDx identifies eligible patients by detecting ESR1 mutations.
• Phase 3 VERITAC-2 trial demonstrated improved progression-free survival (5.0 vs 2.1 months) and higher objective response rate (19% vs 4%) compared to fulvestrant.
• Safety profile includes warnings for QTc interval prolongation and embryo-fetal toxicity; patients should be monitored accordingly.
• The FDA expedited approval via the Assessment Aid process, granting approval one month before the target date.